PURPOSE: We report on the biodistribution and internal radiation dosimetry in humans of [(18)F]fluciclovine, a synthetic L-leucine analogue being investigated as a potential diagnostic biomarker for neoplasia. METHODS: Whole-body positron emission tomography (PET) scans of 6 healthy volunteers were acquired at up to 16 time points up to about 5 h after a bolus administration of [(18)F]fluciclovine (153.8 ± 2.2 MBq). Venous blood samples were taken up to about 4 h post-injection from which (18)F activity concentrations in whole blood and plasma were measured. Urine was collected as voided up to 4 h post-injection, from which the excreted (18)F activity was measured. Absolute values of the (18)F activity contained in up to 11 source regions (brain, salivary glands, lung, heart, pancreas, spleen, liver, red bone marrow, kidneys, uterus and urinary bladder contents) were determined directly from quantitative analysis of the images. For each source region, the (18)F activity decay-corrected and normalised to that injected, as a function of time, was fit by an analytical function which was subsequently integrated to yield the cumulated activity normalised to the injected activity. These normalised cumulated activities were then used as input to the Organ Level INternal Dose Assessment/EXponential Modelling (OLINDA/EXM) package to calculate the internal radiation dosimetry of each subject following the Medical Internal Radiation Dose (MIRD) schema. An effective dose was then estimated for each subject. RESULTS: [(18)F]Fluciclovine was clinically well tolerated in this study. Very little (18)F was excreted with only a mean value of 3.3% present in the urine at about 4 h post-injection; no activity within the intestinal contents was noted. The highest mean initial uptakes were measured in the liver (13.8%), red bone marrow (11.1%) and lung (7.1%). The highest mean radiation absorbed doses per unit administered activity were received by the pancreas (102.2 μGy/MBq), the cardiac wall (51.7 μGy/MBq) and the uterine wall (44.6 μGy/MBq). The mean effective dose per unit administered activity was 22.1 μSv/MBq. CONCLUSION: The internal radiation dosimetry of [(18)F]fluciclovine appears acceptable for PET imaging.
PURPOSE: We report on the biodistribution and internal radiation dosimetry in humans of [(18)F]fluciclovine, a synthetic L-leucine analogue being investigated as a potential diagnostic biomarker for neoplasia. METHODS: Whole-body positron emission tomography (PET) scans of 6 healthy volunteers were acquired at up to 16 time points up to about 5 h after a bolus administration of [(18)F]fluciclovine (153.8 ± 2.2 MBq). Venous blood samples were taken up to about 4 h post-injection from which (18)F activity concentrations in whole blood and plasma were measured. Urine was collected as voided up to 4 h post-injection, from which the excreted (18)F activity was measured. Absolute values of the (18)F activity contained in up to 11 source regions (brain, salivary glands, lung, heart, pancreas, spleen, liver, red bone marrow, kidneys, uterus and urinary bladder contents) were determined directly from quantitative analysis of the images. For each source region, the (18)F activity decay-corrected and normalised to that injected, as a function of time, was fit by an analytical function which was subsequently integrated to yield the cumulated activity normalised to the injected activity. These normalised cumulated activities were then used as input to the Organ Level INternal Dose Assessment/EXponential Modelling (OLINDA/EXM) package to calculate the internal radiation dosimetry of each subject following the Medical Internal Radiation Dose (MIRD) schema. An effective dose was then estimated for each subject. RESULTS: [(18)F]Fluciclovine was clinically well tolerated in this study. Very little (18)F was excreted with only a mean value of 3.3% present in the urine at about 4 h post-injection; no activity within the intestinal contents was noted. The highest mean initial uptakes were measured in the liver (13.8%), red bone marrow (11.1%) and lung (7.1%). The highest mean radiation absorbed doses per unit administered activity were received by the pancreas (102.2 μGy/MBq), the cardiac wall (51.7 μGy/MBq) and the uterine wall (44.6 μGy/MBq). The mean effective dose per unit administered activity was 22.1 μSv/MBq. CONCLUSION: The internal radiation dosimetry of [(18)F]fluciclovine appears acceptable for PET imaging.
Authors: David M Schuster; John R Votaw; Peter T Nieh; Weiping Yu; Jonathon A Nye; Viraj Master; F DuBois Bowman; Muta M Issa; Mark M Goodman Journal: J Nucl Med Date: 2007-01 Impact factor: 10.057
Authors: David R Sprague; Frederick T Chin; Jeih-San Liow; Masahiro Fujita; H Donald Burns; Richard Hargreaves; James B Stubbs; Victor W Pike; Robert B Innis; P David Mozley Journal: J Nucl Med Date: 2007-01 Impact factor: 10.057
Authors: Andor W J M Glaudemans; Roelien H Enting; Mart A A M Heesters; Rudi A J O Dierckx; Ronald W J van Rheenen; Annemiek M E Walenkamp; Riemer H J A Slart Journal: Eur J Nucl Med Mol Imaging Date: 2012-12-12 Impact factor: 9.236
Authors: Jonathon A Nye; David M Schuster; Weiping Yu; Vernon M Camp; Mark M Goodman; John R Votaw Journal: J Nucl Med Date: 2007-05-15 Impact factor: 10.057
Authors: David M Schuster; Cristina Nanni; Stefano Fanti; Shuntaro Oka; Hiroyuki Okudaira; Yusuke Inoue; Jens Sörensen; Rikard Owenius; Peter Choyke; Baris Turkbey; Trond V Bogsrud; Tore Bach-Gansmo; Raghuveer K Halkar; Jonathon A Nye; Oluwaseun A Odewole; Bital Savir-Baruch; Mark M Goodman Journal: J Nucl Med Date: 2014-11-13 Impact factor: 10.057
Authors: Morteza Esmaeili; Nassim Tayari; Tom Scheenen; Mattijs Elschot; Elise Sandsmark; Helena Bertilsson; Arend Heerschap; Kirsten M Selnæs; Tone F Bathen Journal: Front Oncol Date: 2018-11-15 Impact factor: 6.244
Authors: Ephraim E Parent; Dhruv Patel; Jonathon A Nye; Zhuo Li; Jeffrey J Olson; David M Schuster; Mark M Goodman Journal: EJNMMI Res Date: 2020-12-07 Impact factor: 3.138
Authors: Jeremie Calais; Francesco Ceci; Matthias Eiber; Thomas A Hope; Michael S Hofman; Christoph Rischpler; Tore Bach-Gansmo; Cristina Nanni; Bital Savir-Baruch; David Elashoff; Tristan Grogan; Magnus Dahlbom; Roger Slavik; Jeannine Gartmann; Kathleen Nguyen; Vincent Lok; Hossein Jadvar; Amar U Kishan; Matthew B Rettig; Robert E Reiter; Wolfgang P Fendler; Johannes Czernin Journal: Lancet Oncol Date: 2019-07-30 Impact factor: 41.316